NASDAQ:ACIU

AC Immune Competitors

$6.87

-0.04 (-0.58 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.71

Now: $6.87▼

$7.09

50-Day Range

$6.91

MA: $7.68▼

$8.08

52-Week Range

$4.42

Now: $6.87▼

$13.00

Volume189,214 shs

Average Volume923,648 shs

Market Capitalization$494.21 million

P/E RatioN/A

Dividend YieldN/A

Beta0.82

AC Immune (NASDAQ:ACIU) Vs. NGM, MORF, KURA, MCRB, MDGL, and MGNX

Should you be buying ACIU stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AC Immune, including NGM Biopharmaceuticals (NGM), Morphic (MORF), Kura Oncology (KURA), Seres Therapeutics (MCRB), Madrigal Pharmaceuticals (MDGL), and MacroGenics (MGNX).

AC Immune vs. NGM Biopharmaceuticals Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for NGM Biopharmaceuticals and AC Immune, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
AC Immune	0	0	1	0	3.00

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, indicating a potential upside of 53.80%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than NGM Biopharmaceuticals.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Earnings and Valuation

This table compares NGM Biopharmaceuticals and AC Immune's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.84	$-42,790,000.00	($0.85)	-29.92
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45

AC Immune has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NGM Biopharmaceuticals and AC Immune's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
AC Immune	-392.56%	-23.88%	-21.85%

Summary

NGM Biopharmaceuticals beats AC Immune on 8 of the 15 factors compared between the two stocks.

AC Immune vs. Morphic Stock

AC Immune (NASDAQ:ACIU) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for AC Immune and Morphic, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	0	0	1	0	3.00
Morphic	0	0	2	0	3.00

AC Immune currently has a consensus target price of $16.00, indicating a potential upside of 132.90%. Morphic has a consensus target price of $63.3333, indicating a potential upside of 6.71%. Given AC Immune's higher possible upside, research analysts clearly believe AC Immune is more favorable than Morphic.

Profitability

This table compares AC Immune and Morphic's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AC Immune	-392.56%	-23.88%	-21.85%
Morphic	N/A	-36.62%	-20.69%

Risk and Volatility

AC Immune has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 39.5% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AC Immune and Morphic's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45
Morphic	$16.98 million	113.42	$-43,330,000.00	($2.69)	-22.06

AC Immune has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Summary

Morphic beats AC Immune on 7 of the 13 factors compared between the two stocks.

AC Immune vs. Kura Oncology Stock

AC Immune (NASDAQ:ACIU) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional and Insider Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares AC Immune and Kura Oncology's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45
Kura Oncology	N/A	N/A	$-63,140,000.00	($1.51)	-18.92

AC Immune has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for AC Immune and Kura Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	0	0	1	0	3.00
Kura Oncology	0	1	10	0	2.91

AC Immune currently has a consensus target price of $16.00, suggesting a potential upside of 132.90%. Kura Oncology has a consensus target price of $39.5455, suggesting a potential upside of 38.42%. Given AC Immune's stronger consensus rating and higher possible upside, equities research analysts clearly believe AC Immune is more favorable than Kura Oncology.

Risk and Volatility

AC Immune has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares AC Immune and Kura Oncology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AC Immune	-392.56%	-23.88%	-21.85%
Kura Oncology	N/A	-30.96%	-28.02%

Summary

AC Immune beats Kura Oncology on 8 of the 13 factors compared between the two stocks.

AC Immune vs. Seres Therapeutics Stock

Seres Therapeutics (NASDAQ:MCRB) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Risk and Volatility

Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seres Therapeutics and AC Immune's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$34.51 million	54.60	$-70,280,000.00	($1.20)	-17.15
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45

AC Immune has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seres Therapeutics and AC Immune's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%
AC Immune	-392.56%	-23.88%	-21.85%

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Seres Therapeutics and AC Immune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0	1	6	0	2.86
AC Immune	0	0	1	0	3.00

Seres Therapeutics currently has a consensus price target of $38.1667, indicating a potential upside of 85.46%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Seres Therapeutics.

Summary

AC Immune beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.

AC Immune vs. Madrigal Pharmaceuticals Stock

Madrigal Pharmaceuticals (NASDAQ:MDGL) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of AC Immune shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Madrigal Pharmaceuticals and AC Immune, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	0	3	7	0	2.70
AC Immune	0	0	1	0	3.00

Madrigal Pharmaceuticals currently has a consensus price target of $167.60, indicating a potential upside of 43.22%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Madrigal Pharmaceuticals.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and AC Immune's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	$-83,950,000.00	($5.45)	-21.47
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45

AC Immune has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Madrigal Pharmaceuticals and AC Immune's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-47.64%	-43.21%
AC Immune	-392.56%	-23.88%	-21.85%

Summary

AC Immune beats Madrigal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

AC Immune vs. MacroGenics Stock

MacroGenics (NASDAQ:MGNX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares MacroGenics and AC Immune's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MacroGenics	-204.31%	-65.84%	-49.41%
AC Immune	-392.56%	-23.88%	-21.85%

Earnings and Valuation

This table compares MacroGenics and AC Immune's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$64.19 million	29.11	$-151,810,000.00	($3.16)	-9.86
AC Immune	$111.75 million	4.42	$45.74 million	$0.60	11.45

AC Immune has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MacroGenics has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MacroGenics and AC Immune, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1	1	9	0	2.73
AC Immune	0	0	1	0	3.00

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. AC Immune has a consensus target price of $16.00, suggesting a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than MacroGenics.

Summary

AC Immune beats MacroGenics on 8 of the 14 factors compared between the two stocks.